STAAR SURGICAL COMPANY

32.47 $ -0.98%

Add to a list

Valuation: STAAR Surgical Company

Capitalization 1.62B 1.39B 1.27B 1.2B 2.23B 155B 2.27B 15.13B 5.91B 73.95B 6.07B 5.94B 257B P/E ratio 2026 *
111x
P/E ratio 2027 * 63.5x
Enterprise value 1.62B 1.39B 1.27B 1.2B 2.23B 155B 2.27B 15.13B 5.91B 73.95B 6.07B 5.94B 257B EV / Sales 2026 *
4.84x
EV / Sales 2027 * 4.49x
Free-Float
98.54%
Yield 2026 *
-
Yield 2027 * -
1 day-0.98%
1 week+1.25%
Current month+23.18%
1 month+26.49%
3 months+64.41%
6 months+22.34%
Current year+40.62%
1 week 31.51
Extreme 31.51
33.57
1 month 25.2
Extreme 25.205
35.87
Current year 15.58
Extreme 15.585
35.87
1 year 15.58
Extreme 15.585
35.87
3 years 13.5
Extreme 13.5
60.79
5 years 13.5
Extreme 13.5
163.08
10 years 5.12
Extreme 5.12
163.08
Manager TitleAgeSince
Chief Executive Officer 68 2026-01-31
Chief Executive Officer 50 2026-01-31
Chief Tech/Sci/R&D Officer 64 2017-09-30
Director TitleAgeSince
Director/Board Member 43 2023-11-30
Director/Board Member 55 2024-03-11
Director/Board Member 62 2024-03-11
Change 5d. change 1-year change 3-years change Capi.($)
-0.98%+1.25%+73.82%-46.17% 1.62B
-0.41%+3.48%-33.43%-15.98% 152B
+0.58%+3.22%-2.58%-10.16% 101B
+0.59%-4.69%+46.24%+61.13% 55.13B
+3.57%+6.67%-5.97%+60.71% 53.49B
+0.94%+2.90%-13.86%-39.80% 40.68B
-0.24%+2.27% - - 31.3B
+0.28%+16.99%-14.68%-38.23% 27.82B
+0.09%+4.47%+53.91%-7.11% 22.35B
-2.92%+1.91%-14.39%+11.71% 22.19B
Average +0.16%+3.85%+9.90%-2.66% 50.77B
Weighted average by Cap. +0.40%+3.46%-6.48%+1.05%

Financials

2026 *2027 *
Net sales 334M 288M 263M 249M 462M 31.95B 469M 3.13B 1.22B 15.29B 1.25B 1.23B 53.19B 360M 310M 283M 268M 497M 34.38B 505M 3.37B 1.31B 16.46B 1.35B 1.32B 57.25B
Net income 14.9M 12.85M 11.71M 11.09M 20.59M 1.42B 20.91M 139M 54.43M 682M 55.92M 54.74M 2.37B 26.65M 22.98M 20.94M 19.83M 36.83M 2.55B 37.39M 249M 97.36M 1.22B 100M 97.91M 4.24B
Net Debt - -
Logo STAAR Surgical Company
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
Employees
921
Date Price Change Volume
26-05-22 32.47 $ -0.98% 739K
26-05-21 32.79 $ -0.79% 1.24M
26-05-20 33.05 $ +1.38% 652K
26-05-19 32.60 $ +0.90% 812K
26-05-18 32.31 $ +0.75% 1.07M
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
32.47USD
Average target price
29.67USD
Spread / Average Target
-8.63%

Quarterly revenue - Rate of surprise